Pharmafile Logo
Pharmafocus logo
Advanced Search

MDMA

Showing 13 posts of 13 posts found.

PharmAla receives MDMA research grant from Ontario Centre of Innovation

June 12, 2023
Research and Development MDMA, PharmAla, Psychiatry, in silico, research grant

Canadian biotechnology company PharmAla has announced that it has been awarded a research grant from the Ontario Centre of Innovation …

News
brain_anatomy_medical_head_skull_digital_3_d_x_ray_xray_psychedelic_3720x2631

Brain imaging biomarker could predict how psychiatric disorder patients respond to treatment

October 21, 2020
Research and Development MDMA, PTSD

A recent study has indicated that a newly identified brain imaging biomarker could help match patients with psychiatric disorders with …

News
800px-lsd_tabs

First clinical trial for MDMA and LSD combination set to go ahead

August 28, 2020
Medical Communications LSD, MDMA, PTSD

Researchers are set to investigate a combined dose of LSD and MDMA to treat patients undergoing psychotherapy. The Phase 1 …

News
mdma

Study finds that MDMA has long-term benefits for treating PTSD

June 11, 2020
Business Services MDMA, PTSD

PTSD patients being treated with MDMA experience numerous beneficial effects that hold strong for well after a year after completing …

News
fda

FDA advises recall of diabetes drug metformin over carcinogen concerns

May 29, 2020
Medical Communications Carcinogens, MDMA

The FDA has asked that multiple pharmaceutical companies recall the formulations of their diabetes drug metformin after the regulatory body …

News
chandler-01

FDA puts MDMA therapy for PTSD on its Expanded Access program

January 24, 2020
Medical Communications Expanded Access, MAPS, MDMA, PTSD, pharmaceuticals, psychedelics, war

The FDA has made MDMA treatment for PTSD more accessible by putting it on the Expanded Access program. 10 sites …

News
fda-headquarters-gty-jc-181127_hpmain_12x5_608

FDA investigating if carcinogen NDMA is in diabetes drug

December 6, 2019
Medical Communications FDA, Health Canada, MDMA, NDMA, carcinogen, diabetes

The FDA is looking into if the diabetes drug metformin has unsafe levels of a cancer-causing chemical. This comes after …

News
ecstasy

Patients to recieve MDMA-assisted psychotherapy on ‘compassionate’ grounds in Israel

February 28, 2019
Research and Development MDMA, PTSD, drugs, mental health, psychedelics

The Israeli Health Ministry has approved the compassionate use of MDMA-assisted psychotherapy for 50 patients with post-traumatic stress disorder (PTSD). …

News
maps-2018-01-boulder-staged-lana-marcela-bruce-bryce-img_20180128_135008_preview

Psychedelic therapy: A new approach to mental health

December 10, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing LSD, MDMA, controlled substances, depression, mental health, pharma, psychotherapy

In November 2018, a Phase 2 clinical trial found that 76% of patients who underwent MDMA-assisted psychotherapy no longer had …

Feature
display-dummy-757451_1920

76% of patients no longer experience PTSD a year after MDMA-assisted psychotherapy

November 6, 2018
Manufacturing and Production, Research and Development MDMA, PTSD, mental health, psychotherapy, research

Promising phase II results suggest that MDMA-assisted psychotherapy may be an “innovative, efficacious treatment for posttraumatic stress disorder,” according to …

News
ecstasy_monogram

Recreational drug MDMA proves efficacy in reducing PTSD symptoms, new study finds

May 3, 2018
Research and Development MDMA, PTSD, pharma

Promising new findings have been revealed in the efficacy of MDMA in treating post-traumatic stress disorder (PTSD).

News
ecstasy_monogram

FDA fast-tracks recreational drug MDMA for treatment of PTSD

August 30, 2017
Research and Development, Sales and Marketing FDA, MDMA, PTSD, life sciences, pharma, pharmaceuticals

In another leap forward for the promising treatment, the FDA has announced that it has granted Breakthrough Therapy Designation to …

News
shutterstock_204190579

MDMA trials get FDA backing for PTSD treatment

November 30, 2016
Research and Development FDA, MDMA, PTSD

The FDA have given the go-ahead to Phase 3 clinical trials investigating the efficacy of MDMA (Methylenedioxymethamphetamine) for treating post-traumatic …

News

Latest content

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024

AskBio initiates phase 2 Parkinson’s trial recruitment

June 26, 2024

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024